Literature DB >> 18359967

Quetiapine: treatment for substance abuse and drug of abuse.

Michael J Hanley1, George A Kenna.   

Abstract

PURPOSE: The use of quetiapine as a drug to treat various substance use disorders as well as a drug of abuse is examined.
SUMMARY: Quetiapine's effectiveness in treating schizophrenia and bipolar disorder is well-known; however, growing evidence has indicated that it may be useful in the treatment of various substance use disorders. Small-scale studies have been conducted to investigate the potential benefit of quetiapine in patients dependent on alcohol, cocaine, and amphetamines. The results of these two studies provide some evidence that quetiapine may benefit patients diagnosed with a mental illness who are also dependent on cocaine, amphetamines, or both, though more rigorous studies are needed. An unforeseen use of antipsychotics, specifically quetiapine, as drugs of abuse has emerged. Since antipsychotics are not classified as controlled substances, the majority of clinicians may not consider the diversion of antipsychotics for recreational purposes, but evidence of this is increasing, particularly in incarcerated individuals. Intravenous quetiapine abuse was first reported in the literature in 2005. Although most cases of quetiapine abuse have been reported in the correctional setting, inappropriate quetiapine use within the community has been documented. Thus far, all of the documented cases have involved patients with a prior history of substance abuse. Clinicians must be cognizant of the potential for quetiapine as a treatment for substance use disorders and as a drug of abuse.
CONCLUSION: Quetiapine is a promising treatment for substance use disorders alone or combined with other psychiatric diagnoses, such as bipolar disorder and schizophrenia. Quetiapine abuse has also been documented, particularly in the correctional setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359967     DOI: 10.2146/ajhp070112

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  11 in total

1.  Off-label use of atypical antipsychotics: cause for concern?

Authors:  Andrew McKean; Erik Monasterio
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

2.  Is seroquel developing an illicit reputation for misuse/abuse?

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2010-01

3.  The toxicology and comorbidities of fatal cases involving quetiapine.

Authors:  Jennifer L Pilgrim; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2013-02-09       Impact factor: 2.007

4.  Evaluation of the Reinforcing Effect of Quetiapine, Alone and in Combination with Cocaine, in Rhesus Monkeys.

Authors:  Robert E Brutcher; Susan H Nader; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2015-12-07       Impact factor: 4.030

5.  Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN).

Authors:  Margaret E Mattson; Victoria A Albright; Joanna Yoon; Carol L Council
Journal:  Subst Abuse       Date:  2015-05-24

6.  Non-medical use of olanzapine by people on methadone treatment.

Authors:  Philip David James; Ali Shaik Fida; Pavel Konovalov; Bobby P Smyth
Journal:  BJPsych Bull       Date:  2016-12

7.  Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics.

Authors:  Kirk E Evoy; Chengwen Teng; Victor G Encarnacion; Brian Frescas; John Hakim; Stephen Saklad; Christopher R Frei
Journal:  Subst Abuse       Date:  2019-05-01

8.  Norbuprenorphine Interferences in Urine Drug Testing LC-MS-MS Confirmation Methods from Quetiapine Metabolites.

Authors:  Ana Celia Muñoz-Muñoz; Teresa Pekol; Amber Awad; Phillip Hackett; Lynnea Sullivan; Art Rodrigues; Erin Brelsford; Richard Engert; Debra Savery; Lawrence Andrade
Journal:  J Anal Toxicol       Date:  2022-08-13       Impact factor: 3.220

9.  New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine.

Authors:  Bernhard T Baune
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

10.  Effect of Abstinence on Depression, Anxiety, and Quality of Life in Chronic Methamphetamine Users in a Therapeutic Community.

Authors:  Maryam Bagheri; Azarakhsh Mokri; Aliakbar Khosravi; Kourosh Kabir
Journal:  Int J High Risk Behav Addict       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.